Alpha Tau Medical (DRTS) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed NovoCure (NVCR) over the past year, gaining 245.0% versus a gain of 3.5%. Over five years, DRTS leads with a +44.1% price change compared with -86.9% for NVCR. NovoCure is the larger company by market cap ($1.71 billion vs $1.32 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | NVCR |
|---|---|---|
| Share price | $14.25 | $14.66 |
| Market cap | $1.32B | $1.71B |
| 1-day change | -1.59% | -2.07% |
| YTD return | +187.88% | +13.38% |
| 1-year return | +245.04% | +3.53% |
| 5-year return | +44.08% | -86.94% |
| EPS (TTM) | $-1.04 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $21.45 |
| 52-week low | $3.43 | $9.82 |
| Distance from 52-week high | -9.75% | -31.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +24.91% | +83.22% |
| Average volume | 566.95K | 1.42M |
| Shares outstanding | 92.48M | 116.45M |
| Employees | 121 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed NVCR by 241.5 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
DRTS vs NVCR FAQ
Which is bigger, Alpha Tau Medical or NovoCure?
NovoCure (NVCR) is larger, with a market capitalization of $1.71B compared with $1.32B for Alpha Tau Medical (DRTS).
Which stock has performed better over the past year, DRTS or NVCR?
DRTS returned +245.04% over the past 12 months, compared with +3.53% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and NovoCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.